From:  Safety and efficacy of delivering systemic treatments concomitantly with whole-brain radiotherapy: a prospective, observational, single-institution study

 Demographics of the patient population included in the analysis.

Stratification factorsPatientsN%
Therapy groupNon systemic6363.6%
Systemic3636.4%
Biological sexFemale4242.4%
Male5757.6%
PS ≥ 2No6767.7%
Yes3232.3%
Number of brain metastasesNo brain metastasis (GTR)44.0%
1 brain metastasis2626.3%
2–4 brain metastasis4040.4%
> 4 brain metastasis2929.3%
Systemic metastases in addition to brain metastasesNo4141.4%
Yes5858.6%
Neurological symptomsNo3434.3%
Yes6565.7%
Lung adenocarcinomaNo6565.7%
Yes3434.3%

PS: performance status; GTR: gross tumor resection.